Top Markets
Coin of the day
Catalent, Inc. Catalent, Inc.

Catalent, Inc.

CTLT
Rangering i aksjer #1926
Catalent, Inc., operating globally through its various subsidiaries,... Catalent, Inc., operating globally through its various subsidiaries, specializes in the development and production of comprehensive solutions for a wide array of products, including pharmaceutical drugs, protein-based biologics, advanced cell and gene therapies, and consumer health items. The company's operations are strategically divided into four key segments: Biologics; Softgel and Oral Technologies; Oral and Specialty Delivery; and Clinical Supply Services. The Softgel and Oral Technologies division focuses on the formulation, development, and manufacturing of soft capsules. These are utilized in a diverse range of client products, such as prescription medications, over-the-counter drugs, nutritional supplements, unit-dose cosmetics, and medicinal preparations for animal health. Within the Biologics segment, Catalent undertakes the creation of biologic cell lines, develops and manufactures both cell therapy and viral-based gene therapy, and handles the formulation and production of parenteral dose forms, including vials, prefilled syringes, and cartridges. This segment also provides essential analytical development and testing capabilities. The Oral and Specialty Delivery segment offers extensive formulation, development, and manufacturing expertise across various technologies. It provides integrated downstream solutions spanning clinical development and commercial supply. This segment also features a dedicated oral delivery solutions platform, encompassing preclinical screening, formulation, analytical development, and current good manufacturing practices (cGMP) services. Finally, the Clinical Supply Services segment delivers vital support for drug and biologic clinical trials. Its services include manufacturing, specialized packaging, secure storage, efficient distribution, and comprehensive inventory management. This segment also offers "FastChain," a demand-led clinical supply service. Catalent serves a broad client base, including pharmaceutical, biotechnology, and consumer health organizations, alongside companies in other healthcare sectors like animal health and medical devices, and even the cosmetics industry. The company was founded in 2007 and maintains its headquarters in Somerset, New Jersey.
Aksjekurs
$63.48
Sist synkronisert: 2024-12-17
Markedsverdi
$11.52B
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
US
Handel Catalent, Inc. (CTLT)

Kategori

P/E-forhold for Catalent, Inc. (CTLT)
P/E-forhold per August 2026 TTM: -11.02
Ifølge Catalent, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) -11.02. Ved slutten av 2023 hadde selskapet en P/E på -33.83.
P/E-forholdshistorikk for Catalent, Inc. fra 2011 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
2026 (TTM) -11.02 13.03%
2024 -9.75 -71.19%
2023 -33.83 -189.39%
2022 37.84 21.87%
2021 31.05 -51.08%
2020 63.47 10.50%
2019 57.44 -12.63%
2018 65.74 64.52%
2017 39.96 55.29%
2016 25.73 55.29%
2015 16.57 -88.55%
2014 144.74 -388.22%
2013 -50.22 -47.75%
2012 -96.12 121.31%
2011 -43.43 0.00%
P/E-forhold for lignende selskaper eller konkurrenter
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.